Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Huaize Geng, Jianhua Chen et al.|Signal Transduction and Targeted Therapy|2022Cited by 35
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Xiaoyan Kang, Jianhua Chen et al.|BMC Medicine|2023Cited by 24
Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.Gongyan Chen, Yuankai Shi, Xiang Wang et al.|Journal of Clinical Oncology|2022Cited by 5